| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $57,037,138 | 22 | 100 |
| Maraldo David R. | EVP & Pres. MMD | 0 | $0 | 1 | $345,736 | $-345,736 |
| Downing Cristal N | Chief Comm. & Public Afrs Ofcr | 0 | $0 | 1 | $616,395 | $-616,395 |
| Smart Dalton E. III | SVP Fin. - Global Controller | 0 | $0 | 1 | $765,920 | $-765,920 |
| Oosthuizen Johannes Jacobus | President, U.S. Market | 0 | $0 | 1 | $1.83M | $-1.83M |
| Li Dean Y | Executive VP & President, MRL | 0 | $0 | 2 | $2.99M | $-2.99M |
| Litchfield Caroline | EVP & CFO | 0 | $0 | 1 | $5.02M | $-5.02M |
| Davis Robert M | Chairman, CEO & President | 0 | $0 | 1 | $5.6M | $-5.6M |
| Williams David Michael | EVP,Chief Info&Digital Officer | 0 | $0 | 3 | $5.8M | $-5.8M |
| Guindo Chirfi | Chief Marketing Officer | 0 | $0 | 5 | $8.15M | $-8.15M |
| DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | 0 | $0 | 5 | $11.29M | $-11.29M |
| Zachary Jennifer | EVP, General Counsel | 0 | $0 | 2 | $15.35M | $-15.35M |
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the …
Over the last 12 months, insiders at Merck & Co., Inc. have bought $0 and sold $57.04M worth of Merck & Co., Inc. stock.
On average, over the past 5 years, insiders at Merck & Co., Inc. have bought $810,918 and sold $104.75M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,833 shares for transaction amount of $250,000 was made by THULIN INGE G (director) on 2025‑02‑06.
| 2026-08-13 | Sale | Guindo Chirfi | EVP, Access, Policy & Comms | 10,000 0.0004% | $135.00 | $1.35M | +8.99% | |
| 2026-08-12 | Sale | DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | 11,699 0.0005% | $131.63 | $1.54M | +11.07% | |
| 2026-08-12 | Sale | Zachary Jennifer | EVP, General Counsel | 80,315 0.0033% | $133.46 | $10.72M | +11.07% | |
| 2026-08-11 | Sale | DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | 12,837 0.0005% | $131.76 | $1.69M | +13.12% | |
| 2026-08-10 | Sale | DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | 20,784 0.0008% | $130.43 | $2.71M | +12.56% | |
| 2026-08-06 | Sale | DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | 6,050 0.0002% | $130.38 | $788,773 | +14.52% | |
| 2026-08-06 | Sale | Guindo Chirfi | EVP, Access, Policy & Comms | 15,000 0.0006% | $131.00 | $1.97M | +14.52% | |
| 2026-08-05 | Sale | Williams David Michael | EVP,Chief Info&Digital Officer | 34,705 0.0014% | $128.77 | $4.47M | +14.41% | |
| 2026-08-05 | Sale | Maraldo David R. | EVP & Pres. MMD | 2,686 0.0001% | $128.72 | $345,736 | +14.41% | |
| 2026-02-12 | Sale | Guindo Chirfi | Chief Marketing Officer | 10,000 0.0004% | $121.46 | $1.21M | +4.59% | |
| 2026-02-10 | Sale | Li Dean Y | Executive VP & President, MRL | 10,235 0.0004% | $117.52 | $1.2M | +5.85% | |
| 2026-02-09 | Sale | Guindo Chirfi | Chief Marketing Officer | 10,000 0.0004% | $118.41 | $1.18M | +5.33% | |
| 2026-02-09 | Sale | Zachary Jennifer | EVP, General Counsel | 38,835 0.0016% | $119.15 | $4.63M | +5.33% | |
| 2026-02-06 | Sale | DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | 37,685 0.0015% | $120.92 | $4.56M | +1.60% | |
| 2026-02-06 | Sale | Williams David Michael | EVP,Chief Info&Digital Officer | 5,000 0.0002% | $121.91 | $609,525 | +1.60% | |
| 2026-02-06 | Sale | Oosthuizen Johannes Jacobus | President, U.S. Market | 15,000 0.0006% | $121.87 | $1.83M | +1.60% | |
| 2026-02-05 | Sale | Guindo Chirfi | Chief Marketing Officer | 20,000 0.0008% | $121.88 | $2.44M | +3.40% | |
| 2026-02-04 | Sale | Davis Robert M | Chairman, CEO & President | 47,434 0.0019% | $118.04 | $5.6M | +4.64% | |
| 2026-02-04 | Sale | Li Dean Y | Executive VP & President, MRL | 15,087 0.0006% | $118.77 | $1.79M | +4.64% | |
| 2026-02-04 | Sale | Litchfield Caroline | EVP & CFO | 41,997 0.0017% | $119.61 | $5.02M | +4.64% |
| HASSAN FRED | Chairman and CEO | 720800 0.0292% | $104.28M | 2 | 0 | <0.0001% |
| FRAZIER KENNETH C | Executive Chair | 700653 0.0284% | $101.36M | 1 | 40 | +21.76% |
| SABATINO THOMAS J JR | Executive Vice President | 309535 0.0125% | $44.78M | 1 | 0 | |
| BERTOLINI ROBERT J | Executive Vice President | 65000 0.0026% | $9.4M | 1 | 0 | |
| KELLOGG PETER N | Exe V-P & CFO | 53999 0.0022% | $7.81M | 1 | 0 | +24.73% |
| Romanelli Joseph | President, Human Health Int?l | 19569 0.0008% | $2.83M | 8 | 4 | +0.33% |
| BAKER DOUGLAS M JR | director | 16000 0.0006% | $2.31M | 1 | 0 | <0.0001% |
| Colligan Thomas J | director | 15024 0.0006% | $2.17M | 2 | 0 | +16.73% |
| STAHL JACK L | director | 10000 0.0004% | $1.45M | 2 | 0 | <0.0001% |
| THULIN INGE G | director | 2933 0.0001% | $424,297.00 | 1 | 0 | <0.0001% |
$1,927,310,793 | 31 | 28.02% | $1,325.87B | |
$364,368,632 | 29 | 9.65% | $36.8B | |
$6,224,380 | 25 | 3.58% | $640.75B | |
$23,541,811 | 22 | 6.43% | $126.14B | |
$28,542,809 | 19 | 26.39% | $505.4B |
| Increased Positions | 1,919 | +54.06% | 144M | +7.44% |
| Decreased Positions | 1,600 | -45.07% | 112M | -5.76% |
| New Positions | 502 | New | 34M | New |
| Sold Out Positions | 140 | Sold Out | 13M | Sold Out |
| Total Postitions | 3,869 | +8.99% | 2B | +1.68% |
| Vanguard Group Inc | $26.84M | 10.16% | 252.14M | -777,516 | -0.31% | 2025-09-30 |
| Blackrock, Inc. | $22.87M | 8.66% | 214.88M | -3M | -1.59% | 2025-09-30 |
| State Street Corp | $12.58M | 4.76% | 118.18M | -313,686 | -0.27% | 2025-09-30 |
| Wellington Management Group Llp | $8.01M | 3.03% | 75.28M | -2M | -2.05% | 2025-09-30 |
| Geode Capital Management, Llc | $6.37M | 2.41% | 59.8M | +846,193 | +1.44% | 2025-09-30 |
| Charles Schwab Investment Management Inc | $5.72M | 2.16% | 53.7M | -166,006 | -0.31% | 2025-09-30 |
| Morgan Stanley | $4.75M | 1.8% | 44.59M | +385,841 | +0.87% | 2025-09-30 |
| Norges Bank | $3.84M | 1.46% | 36.11M | +1M | +3.23% | 2025-06-30 |
| Jpmorgan Chase & Co | $3.75M | 1.42% | 35.2M | +3M | +10.62% | 2025-09-30 |
| Fmr Llc | $3.56M | 1.35% | 33.43M | +2M | +5.89% | 2025-09-30 |